Pfizer Inc. (PFE)
After hours:
| Previous close | 53.04 |
| Open | 53.71 |
| Bid | 0.00 x 1200 |
| Ask | 0.00 x 3000 |
| Day's range | 53.10 - 54.41 |
| 52-week range | 33.36 - 55.70 |
| Volume | |
| Avg. volume | 33,175,322 |
| Market cap | 304.61B |
| Beta (5Y monthly) | 0.67 |
| PE ratio (TTM) | 15.50 |
| EPS (TTM) | 3.50 |
| Earnings date | 31 Jan 2022 - 04 Feb 2022 |
| Forward dividend & yield | 1.56 (2.87%) |
| Ex-dividend date | 04 Nov 2021 |
| 1y target est | N/A |
- Motley Fool
Why Moderna Is the Biggest Winner From COVID Boosters So Far
Some Americans could prefer Moderna's booster because of perceptions that it offers higher efficacy.
- Motley Fool
Here's Why Merck Lost Nearly $40 Billion in Value During November
Shares of pharma giant Merck (NYSE: MRK) fell by 14.9% during the month of November, according to data from S&P Global Market Intelligence. Although the drugmaker did take a hit from a clinical setback for its once-weekly oral treatment, MK-8507, for HIV-1 infection last month, the main reason Merck's stock slumped in November is the evolving situation surrounding its oral coronavirus pill molnupiravir. In brief, this COVID-19 pill, which is being jointly developed with privately held Ridgeback Biotherapeutics, exhibited a significant drop in efficacy following the final analysis of the full data set, compared to a prior interim data readout.
- Yahoo Finance
Guess who pays for all those millions of COVID-19 vaccines
Omicron happened this week. So as the medical world shifts to a yet-to-be-determined degree, a question comes to mind: Who will pay for all this? In fact, who’s paid for all the COVID fighting to date?
